Latanoprost

Generic Name: Latanoprost

Brand Names: Iyuzeh, Rocklatan, Xalacom, Xalatan, Xelpros, Catiolanze

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₄₀O_₅

CAS Number: 130209-82-4

Unique Ingredient Identifier: 6Z5B6HVF6O

Background: Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use does not normally result in systemic adverse effects l...

Indication: Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension. It is available as monotherapy or in a combination product with netarsudil or timolol.
...

Associated Conditions: Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Open Angle Glaucoma (OAG)

Associated Therapies: -

Clinical Trials

Effects of Anti-Glaucoma Medications on the Ocular Surface

Phase 4

Terminated

Conditions: Glaucoma

Interventions: Drug: Travoprost
Drug: Latanoprost

First Posted Date: 2011-03-15

Last Posted Date: 2017-03-16

Lead Sponsor: Massachusetts Eye and Ear Infirmary

Target Recruit Count: 14

Registration Number: NCT01315574

Locations: 🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

Phase 2

Completed

Conditions: Ocular Surface Disease
Glaucoma
Ocular Hypertension

Interventions: Drug: Latanoprost
Drug: Travatan Z

First Posted Date: 2010-12-06

Last Posted Date: 2016-06-06

Lead Sponsor: Santen SAS

Target Recruit Count: 105

Registration Number: NCT01254370

Locations: 🇺🇸
Ora (Ophthalmic Research Associates), Andover, Massachusetts, United States

Topical Application of Latanoprost in Diabetic Retinopathy

Phase 4

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: Latanoprost

First Posted Date: 2010-10-21

Last Posted Date: 2014-12-18

Lead Sponsor: University of Aarhus

Target Recruit Count: 27

Registration Number: NCT01225653

Locations: 🇩🇰
Department of Ophthalmology, Århus University Hospital, Århus, Denmark

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Intraocular Pressure

Interventions: Drug: BOL-303259-X
Drug: Latanoprost

First Posted Date: 2010-10-19

Last Posted Date: 2018-07-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 413

Registration Number: NCT01223378

Locations: 🇺🇸
Bausch & Lomb, Inc, Rochester, New York, United States

Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: XALACOM
Drug: Duotrav
Drug: Ganfort

First Posted Date: 2010-09-21

Last Posted Date: 2021-02-02

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 2015

Registration Number: NCT01206361

Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature

Not Applicable

Completed

Conditions: Primary Vascular Dysregulation

Interventions: Drug: Brimonidine
Drug: Latanoprost
Drug: Placebo

First Posted Date: 2010-09-14

Last Posted Date: 2013-12-11

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 40

Registration Number: NCT01201551

Locations: 🇨🇭
University of Basel, Dept. of Ophthalmology, Basel, Switzerland

Safety Study of Latanoprost Slow Release Insert

Phase 1

Terminated

Conditions: Ocular Hypertension (OHT)
Primary Open Angle Glaucoma (POAG)

Interventions: Drug: Latanoprost
Drug: Arm 2
Drug: Latanoprost SR insert

First Posted Date: 2010-08-11

Last Posted Date: 2014-12-08

Lead Sponsor: Daniel Moore

Target Recruit Count: 12

Registration Number: NCT01180062

Locations: 🇺🇸
Univ of Ky Dept of Ophthalmology and Visual Sciences, Lexington, Kentucky, United States

Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma

Not Applicable

Completed

Conditions: Normal Tension Glaucoma

Interventions: Drug: dorzolamide/timolol
Drug: latanoprost

First Posted Date: 2010-08-05

Last Posted Date: 2015-01-08

Lead Sponsor: The Catholic University of Korea

Target Recruit Count: 44

Registration Number: NCT01175902

Locations: 🇰🇷
Seoul St. Mary's hospital, Seoul, Korea, Republic of

Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: Geltim LP 1 mg/g
Drug: Xalatan

First Posted Date: 2010-07-01

Last Posted Date: 2017-04-04

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 150

Registration Number: NCT01155219

Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients

Phase 4

Terminated

Conditions: Glaucoma, Angle-Closure

Interventions: Drug: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution
Drug: latanoprost

First Posted Date: 2010-06-29

Last Posted Date: 2013-02-06

Lead Sponsor: Allergan

Target Recruit Count: 17

Registration Number: NCT01151904

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy